Aneurysmal subarachnoid hemorrhage: pathobiology, current treatment and future directions

References

• van Gijn J, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and management. Brain 2001;124(Pt 2):249-78
   PubMed Web of Science ®Google Scholar
• Nieuwkamp DJ, Setz LE, Algra A, et al. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol 2009;8(7):635-42
   PubMed Web of Science ®Google Scholar
• Kusaka G, Ishikawa M, Nanda A, et al. Signaling pathways for early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2004;24(8):916-25
   PubMed Web of Science ®Google Scholar
• Sehba FA, Pluta RM, Zhang JH. Metamorphosis of subarachnoid hemorrhage research: from delayed vasospasm to early brain injury. Mol Neurobiol 2011;43(1):27-40
   Google Scholar
• Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke 2010;41(10):2391-5
   PubMed Web of Science ®Google Scholar
• Bendel P, Koivisto T, Aikia M, et al. Atrophic enlargement of CSF volume after subarachnoid hemorrhage: correlation with neuropsychological outcome. AJNR Am J Neuroradiol 2010;31(2):370-6
   Google Scholar
• Gross BA, Du R. Vasospasm after arteriovenous malformation rupture. World Neurosurg 2012;78(3-4):300-5
   Google Scholar
• Gross BA, Lin N, Frerichs KU, Du R. Vasospasm after spontaneous angiographically negative subarachnoid hemorrhage. Acta Neurochir (Wien) 2012;154(7):1127-33
   Google Scholar
• Voldby B, Enevoldsen EM. Intracranial pressure changes following aneurysm rupture. Part 1: clinical and angiographic correlations. J Neurosurg 1982;56(2):186-96
   Google Scholar
• Kassell NF, Torner JC, Haley ECJr, et al. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: overall management results. J Neurosurg 1990;73(1):18-36
   PubMed Web of Science ®Google Scholar
• Weir B, Grace M, Hansen J, Rothberg C. Time course of vasospasm in man. J Neurosurg 1978;48(2):173-8
   Google Scholar
• Brown RJ, Kumar A, Dhar R, et al. The relationship between delayed infarcts and angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 2013;72(5):702-7; discussion 707-708
   Google Scholar
• Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL. Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab 2011;31(6):1443-51
   Google Scholar
• Macdonald RL, Higashida RT, Keller E, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke 2012;43(6):1463-9
   PubMed Web of Science ®Google Scholar
• Macdonald RL, Higashida RT, Keller E, et al. Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2). Acta Neurochir Suppl 2013;115:27-31
   Google Scholar
• Nornes H, Aaslid R, Lindegaard KF. Intracranial pulse pressure dynamics in patients with intracranial hypertension. Acta Neurochir (Wien) 1977;38(3-4):177-86
   Google Scholar
• Bederson JB, Levy AL, Ding WH, et al. Acute vasoconstriction after subarachnoid hemorrhage. Neurosurgery 1998;42(2):352-60; Discussion 360-352
   Google Scholar
• Schievink WI, Wijdicks EF, Parisi JE, et al. Sudden death from aneurysmal subarachnoid hemorrhage. Neurology 1995;45(5):871-4
   PubMed Web of Science ®Google Scholar
• Cahill J, Calvert JW, Zhang JH. Mechanisms of early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2006;26(11):1341-53
   PubMed Web of Science ®Google Scholar
• Park S, Yamaguchi M, Zhou C, et al. Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. Stroke 2004;35(10):2412-17
   PubMed Web of Science ®Google Scholar
• Nau R, Haase S, Bunkowski S, Bruck W. Neuronal apoptosis in the dentate gyrus in humans with subarachnoid hemorrhage and cerebral hypoxia. Brain Pathol 2002;12(3):329-36
   PubMed Web of Science ®Google Scholar
• Prunell GF, Svendgaard NA, Alkass K, Mathiesen T. Delayed cell death related to acute cerebral blood flow changes following subarachnoid hemorrhage in the rat brain. J Neurosurg 2005;102(6):1046-54
   PubMed Web of Science ®Google Scholar
• Hasan D, Vermeulen M, Wijdicks EF, et al. Management problems in acute hydrocephalus after subarachnoid hemorrhage. Stroke 1989;20(6):747-53
   PubMed Web of Science ®Google Scholar
• Milhorat TH. Acute hydrocephalus after aneurysmal subarachnoid hemorrhage. Neurosurgery 1987;20(1):15-20
   Google Scholar
• van Asch CJ, van der Schaaf IC, Rinkel GJ. Acute hydrocephalus and cerebral perfusion after aneurysmal subarachnoid hemorrhage. AJNR Am J Neuroradiol 2010;31(1):67-70
   Google Scholar
• Schmidt EA, Silva S, Albucher JF, et al. Cerebral hemodynamic changes induced by a lumbar puncture in good-grade subarachnoid hemorrhage. Cerebrovasc Dis Extra 2012;2(1):52-62
   Google Scholar
• Germano A, d’Avella D, Imperatore C, et al. Time-course of blood-brain barrier permeability changes after experimental subarachnoid haemorrhage. Acta Neurochir (Wien) 2000;142(5):575-80; discussion 580-571
   Google Scholar
• Scholler K, Trinkl A, Klopotowski M, et al. Characterization of microvascular basal lamina damage and blood-brain barrier dysfunction following subarachnoid hemorrhage in rats. Brain Res 2007;1142:237-46
   PubMed Web of Science ®Google Scholar
• Nakagomi T, Kassell NF, Sasaki T, et al. Time course of the blood-arterial wall barrier disruption following experimental subarachnoid haemorrhage. Acta Neurochir (Wien) 1989;98(3-4):176-83
   Google Scholar
• Voldby B, Enevoldsen EM, Jensen FT. Cerebrovascular reactivity in patients with ruptured intracranial aneurysms. J Neurosurg 1985;62(1):59-67
   Google Scholar
• Mustonen T, Koivisto T, Vanninen R, et al. Heterogeneity of cerebral perfusion 1 week after haemorrhage is an independent predictor of clinical outcome in patients with aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2008;79(10):1128-33
   Google Scholar
• Busch E, Beaulieu C, de Crespigny A, et al. Diffusion MR imaging during acute subarachnoid hemorrhage in rats. Editorial Comment Stroke 1998;29(10):2155-61
   Google Scholar
• Liu Y, Soppi V, Mustonen T, et al. Subarachnoid hemorrhage in the subacute stage: elevated apparent diffusion coefficient in normal-appearing brain tissue after treatment. Radiology 2007;242(2):518-25
   Google Scholar
• Claassen J, Carhuapoma JR, Kreiter KT, et al. Global cerebral edema after subarachnoid hemorrhage: frequency, predictors, and impact on outcome. Stroke 2002;33(5):1225-32
   PubMed Web of Science ®Google Scholar
• Badaut J, Lasbennes F, Magistretti PJ, Regli L. Aquaporins in brain: distribution, physiology, and pathophysiology. J Cereb Blood Flow Metab 2002;22(4):367-78
   PubMed Web of Science ®Google Scholar
• Zhou C, Yamaguchi M, Colohan AR, Zhang JH. Role of p53 and apoptosis in cerebral vasospasm after experimental subarachnoid hemorrhage. J Cereb Blood Flow Metab 2005;25(5):572-82
   Google Scholar
• Yatsushige H, Ostrowski RP, Tsubokawa T, et al. Role of c-Jun N-terminal kinase in early brain injury after subarachnoid hemorrhage. J Neurosci Res 2007;85(7):1436-48
   Google Scholar
• Hasegawa Y, Suzuki H, Sozen T, et al. Apoptotic mechanisms for neuronal cells in early brain injury after subarachnoid hemorrhage. Acta Neurochir Suppl 2011;110(Pt 1):43-8
   Google Scholar
• Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6(1):1-9
   PubMed Web of Science ®Google Scholar
• Nishizawa S, Laher I. Signaling mechanisms in cerebral vasospasm. Trends Cardiovasc Med 2005;15(1):24-34
   PubMed Web of Science ®Google Scholar
• Fassbender K, Hodapp B, Rossol S, et al. Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry 2001;70(4):534-7
   PubMedGoogle Scholar
• Chaichana KL, Pradilla G, Huang J, Tamargo RJ. Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage. World Neurosurg 2010;73(1):22-41
   PubMed Web of Science ®Google Scholar
• Polin RS, Bavbek M, Shaffrey ME, et al. Detection of soluble E-selectin, ICAM-1, VCAM-1, and L-selectin in the cerebrospinal fluid of patients after subarachnoid hemorrhage. J Neurosurg 1998;89(4):559-67
   Google Scholar
• Lin CL, Dumont AS, Calisaneller T, et al. Monoclonal antibody against E selectin attenuates subarachnoid hemorrhage-induced cerebral vasospasm. Surg Neurol 2005;64(3):201-5; discussion 205-6
   Google Scholar
• Friedrich B, Muller F, Feiler S, et al. Experimental subarachnoid hemorrhage causes early and long-lasting microarterial constriction and microthrombosis: an in-vivo microscopy study. J Cereb Blood Flow Metab 2012;32(3):447-55
   PubMed Web of Science ®Google Scholar
• Ulm AJ, Tanriover N, Kawashima M, et al. Microsurgical approaches to the perimesencephalic cisterns and related segments of the posterior cerebral artery: comparison using a novel application of image guidance. Neurosurgery 2004;54(6):1313-28
   Google Scholar
• Neil-Dwyer G, Lang DA, Doshi B, et al. Delayed cerebral ischaemia: the pathological substrate. Acta Neurochir (Wien) 1994;131(1-2):137-45
   Google Scholar
• Romano JG, Rabinstein AA, Arheart KL, et al. Microemboli in aneurysmal subarachnoid hemorrhage. J Neuroimaging 2008;18(4):396-401
   Google Scholar
• Sabri M, Ai J, Lakovic K, et al. Mechanisms of microthrombi formation after experimental subarachnoid hemorrhage. Neuroscience 2012;224:26-37
   PubMedGoogle Scholar
• Ostergaard L, Aamand R, Karabegovic S, et al. The role of the microcirculation in delayed cerebral ischemia and chronic degenerative changes after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2013;33(12):1825-37
   Google Scholar
• Baharoglu MI, Germans MR, Rinkel GJ, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2013;8:CD001245
   Google Scholar
• Tsementzis SA, Hitchcock ER, Meyer CH. Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochir (Wien) 1990;102(1-2):1-10
   PubMed Web of Science ®Google Scholar
• Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med 2011;17(4):439-47
   PubMed Web of Science ®Google Scholar
• Dreier JP, Woitzik J, Fabricius M, et al. Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. Brain 2006;129(Pt 12):3224-37
   PubMedGoogle Scholar
• Dreier JP, Ebert N, Priller J, et al. Products of hemolysis in the subarachnoid space inducing spreading ischemia in the cortex and focal necrosis in rats: a model for delayed ischemic neurological deficits after subarachnoid hemorrhage? J Neurosurg 2000;93(4):658-66
   PubMed Web of Science ®Google Scholar
• Hartings JA, Wilson JA, Look AC, et al. Full-band electrocorticography of spreading depolarizations in patients with aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl 2013;115:131-41
   Google Scholar
• Sakowitz OW, Santos E, Nagel A, et al. Clusters of spreading depolarizations are associated with disturbed cerebral metabolism in patients with aneurysmal subarachnoid hemorrhage. Stroke 2013;44(1):220-3
   Google Scholar
• Bosche B, Graf R, Ernestus RI, et al. Recurrent spreading depolarizations after subarachnoid hemorrhage decreases oxygen availability in human cerebral cortex. Ann Neurol 2010;67(5):607-17
   PubMed Web of Science ®Google Scholar
• Dreier JP, Major S, Manning A, et al. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain 2009;132(Pt 7):1866-81
   PubMedGoogle Scholar
• Kleeberg J, Petzold GC, Major S, et al. ET-1 induces cortical spreading depression via activation of the ETA receptor/phospholipase C pathway in vivo. Am J Physiol Heart Circ Physiol 2004;286(4):H1339-46
   PubMed Web of Science ®Google Scholar
• Woitzik J, Dreier JP, Hecht N, et al. Delayed cerebral ischemia and spreading depolarization in absence of angiographic vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2012;32(2):203-12
   PubMed Web of Science ®Google Scholar
• Hertle DN, Dreier JP, Woitzik J, et al. Effect of analgesics and sedatives on the occurrence of spreading depolarizations accompanying acute brain injury. Brain 2012;135(Pt 8):2390-8
   PubMedGoogle Scholar
• Klimo PJr, Browd SR, Pravdenkova S, et al. The posterior petrosal approach: technique and applications in pediatric neurosurgery. J Neurosurg Pediatr 2009;4(4):353-62
   Google Scholar
• Birkeland P. Use of lumbar drain to remove clots in patients admitted to the neuro-ICU after subarachnoid hemorrhage. In: clinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01886521 [Accessed 22 September 2014]
   Google Scholar
• Etminan N, Beseoglu K, Eicker SO, et al. Prospective, randomized, open-label phase II trial on concomitant intraventricular fibrinolysis and low-frequency rotation after severe subarachnoid hemorrhage. Stroke 2013;44(8):2162-8
   Google Scholar
• Hamada J, Mizuno T, Kai Y, et al. Microcatheter intrathecal urokinase infusion into cisterna magna for prevention of cerebral vasospasm: preliminary report. Stroke 2000;31(9):2141-8
   Google Scholar
• Yamamoto T, Esaki T, Nakao Y, Mori K. Efficacy of low-dose tissue-plasminogen activator intracisternal administration for the prevention of cerebral vasospasm after subarachnoid hemorrhage. World Neurosurg 2010;73(6):675-82
   Google Scholar
• Findlay JM. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery 1995;37(5):1026-7
   Google Scholar
• Kramer AH, Fletcher JJ. Locally-administered intrathecal thrombolytics following aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurocrit Care 2011;14(3):489-99
   Google Scholar
• Connolly ESJr., Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012;43(6):1711-37
   PubMed Web of Science ®Google Scholar
• Vergouwen MD, Vermeulen M, de Haan RJ, et al. Dihydropyridine calcium antagonists increase fibrinolytic activity: a systematic review. J Cereb Blood Flow Metab 2007;27(7):1293-308
   PubMed Web of Science ®Google Scholar
• Dreier JP, Windmuller O, Petzold G, et al. Ischemia triggered by red blood cell products in the subarachnoid space is inhibited by nimodipine administration or moderate volume expansion/hemodilution in rats. Neurosurgery 2002;51(6):1457-65; discussion 1465-1457
   PubMed Web of Science ®Google Scholar
• Ohman J, Servo A, Heiskanen O. Risks factors for cerebral infarction in good-grade patients after aneurysmal subarachnoid hemorrhage and surgery: a prospective study. J Neurosurg 1991;74(1):14-20
   Google Scholar
• Desbordes JM, Ades PE, Guggiari M. [Intravenous nimodipine in the treatment of cerebral vasospasm following subarachnoid hemorrhage caused by aneurysm rupture: a comparative multicenter study]. Agressologie 1989;30(7):438-40
   Google Scholar
• Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British Aneurysm Nimodipine Trial. BMJ 1989;298(6674):636-42
   PubMedGoogle Scholar
• Jan M, Buchheit F, Tremoulet M. Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms. Neurosurgery 1988;23(2):154-7
   PubMed Web of Science ®Google Scholar
• Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg 1988;68(4):505-17
   PubMed Web of Science ®Google Scholar
• Neil-Dwyer G, Mee E, Dorrance D, Lowe D. Early intervention with nimodipine in subarachnoid haemorrhage. Eur Heart J 1987;8(Suppl K):41-7
   Google Scholar
• Philippon J, Grob R, Dagreou F, et al. Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir (Wien) 1986;82(3-4):110-14
   PubMed Web of Science ®Google Scholar
• Rinkel GJ, Feigin VL, Algra A, van Gijn J. Circulatory volume expansion therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2004(4):CD000483
   Google Scholar
• Dankbaar JW, Slooter AJ, Rinkel GJ, Schaaf IC. Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review. Crit Care 2010;14(1):R23
   Google Scholar
• Slooter AJ. Induced hypertension for treatment of delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage (HIMALAIA). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01613235 [Accessed 22 September 2014]
   Google Scholar
• Rahme R, Jimenez L, Pyne-Geithman GJ, et al. Endovascular management of posthemorrhagic cerebral vasospasm: indications, technical nuances, and results. Acta Neurochir Suppl 2013;115:107-12
   Google Scholar
• Zwienenberg-Lee M, Hartman J, Rudisill N, et al. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke 2008;39(6):1759-65
   Google Scholar
• Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008;39(11):3015-21
   PubMed Web of Science ®Google Scholar
• Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005;103(1):9-17
   PubMed Web of Science ®Google Scholar
• Wong GK, Poon WS, Chan MT, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke 2010;41(5):921-6
   PubMed Web of Science ®Google Scholar
• Westermaier T, Stetter C, Vince GH, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med 2010;38(5):1284-90
   PubMed Web of Science ®Google Scholar
• Bradford CM, Finfer S, O’Connor A, et al. A randomised controlled trial of induced hypermagnesaemia following aneurysmal subarachnoid haemorrhage. Crit Care Resusc 2013;15(2):119-25
   Google Scholar
• Muroi C, Terzic A, Fortunati M, et al. Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol 2008;69(1):33-9; discussion 39
   PubMedGoogle Scholar
• Wong GK, Chan MT, Boet R, et al. Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: a prospective randomized pilot study. J Neurosurg Anesthesiol 2006;18(2):142-8
   PubMed Web of Science ®Google Scholar
• van den Bergh WM, Algra A, van Kooten F, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke 2005;36(5):1011-15
   PubMed Web of Science ®Google Scholar
• Veyna RS, Seyfried D, Burke DG, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg 2002;96(3):510-14
   PubMed Web of Science ®Google Scholar
• Boet R, Chan MT, Poon WS, et al. Intravenous magnesium sulfate to improve outcome after aneurysmal subarachnoid hemorrhage: interim report from a pilot study. Acta Neurochir Suppl 2005;95:263-4
   PubMedGoogle Scholar
• Dorhout Mees SM, Algra A, Vandertop WP, et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet 2012;380(9836):44-9
   PubMed Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45:89-118
   PubMed Web of Science ®Google Scholar
• Endres M. Statins and stroke. J Cereb Blood Flow Metab 2005;25(9):1093-110
   PubMed Web of Science ®Google Scholar
• Garg K, Sinha S, Kale SS, et al. Role of simvastatin in prevention of vasospasm and improving functional outcome after aneurysmal sub-arachnoid hemorrhage: a prospective, randomized, double-blind, placebo-controlled pilot trial. Br J Neurosurg 2013;27(2):181-6
   PubMed Web of Science ®Google Scholar
• Vergouwen MD, Meijers JC, Geskus RB, et al. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial. J Cereb Blood Flow Metab 2009;29(8):1444-53
   PubMed Web of Science ®Google Scholar
• Chou SH, Smith EE, Badjatia N, et al. A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage. Stroke 2008;39(10):2891-3
   PubMed Web of Science ®Google Scholar
• Tseng MY, Czosnyka M, Richards H, et al. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 2005;36(8):1627-32
   PubMed Web of Science ®Google Scholar
• Tseng MY, Hutchinson PJ, Czosnyka M, et al. Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage. Stroke 2007;38(5):1545-50
   PubMed Web of Science ®Google Scholar
• Kirkpatrick PJ, Turner CL, Smith C, et al. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. Lancet Neurol 2014;13(7):666-75
   PubMed Web of Science ®Google Scholar
• Gaetani P, Pasqualin A, Rodriguez y Baena R, et al. Oxidative stress in the human brain after subarachnoid hemorrhage. J Neurosurg 1998;89(5):748-54
   Google Scholar
• Kavanagh RJ, Kam PC. Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection. Br J Anaesth 2001;86(1):110-19
   Google Scholar
• Haley ECJr, Kassell NF, Alves WM, et al. Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 1995;82(5):786-90
   Google Scholar
• Kassell NF, Haley ECJr, Apperson-Hansen C, Alves WM. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg 1996;84(2):221-8
   Google Scholar
• Haley ECJr, Kassell NF, Apperson-Hansen C, et al. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. J Neurosurg 1997;86(3):467-74
   Google Scholar
• Lanzino G, Kassell NF, Dorsch NW, et al. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa. J Neurosurg 1999;90(6):1011-17
   Google Scholar
• Lanzino G, Kassell NF. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America. J Neurosurg 1999;90(6):1018-24
   Google Scholar
• Zhang S, Wang L, Liu M, Wu B. Tirilazad for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2010(2):CD006778
   Google Scholar
• Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003;93(8):767-75
   PubMed Web of Science ®Google Scholar
• Li H, Peng W, Jian W, et al. ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion. Cardiovasc Diabetol 2012;11:65
   PubMed Web of Science ®Google Scholar
• Asano T, Ikegaki I, Satoh S, et al. Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 1987;241(3):1033-40
   Google Scholar
• Hu E, Lee D. Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases. Curr Opin Investig Drugs 2003;4(9):1065-75
   PubMedGoogle Scholar
• Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992;76(4):571-7
   PubMed Web of Science ®Google Scholar
• Yoneda H, Shirao S, Nakagawara J, et al. A prospective, multicenter, randomized study of the efficacy of eicosapentaenoic acid for cerebral vasospasm: the EVAS study. World Neurosurg 2014;81(2):309-15
   Google Scholar
• Saito I, Asano T, Sano K, et al. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. Neurosurgery 1998;42(2):269-77; discussion 277-268
   PubMed Web of Science ®Google Scholar
• Asano T, Takakura K, Sano K, et al. Effects of a hydroxyl radical scavenger on delayed ischemic neurological deficits following aneurysmal subarachnoid hemorrhage: results of a multicenter, placebo-controlled double-blind trial. J Neurosurg 1996;84(5):792-803
   Google Scholar
• Isahaya K, Yamada K, Yamatoku M, et al. Effects of edaravone, a free radical scavenger, on serum levels of inflammatory biomarkers in acute brain infarction. J Stroke Cerebrovasc Dis 2012;21(2):102-7
   Google Scholar
• Munakata A, Ohkuma H, Nakano T, et al. Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2009;64(3):423-8; discussion 428-429
   Google Scholar
• Hashi K, Takakura K, Sano K, et al. [Intravenous hydrocortisone in large doses in the treatment of delayed ischemic neurological deficits following subarachnoid hemorrhage – results of a multi-center controlled double-blind clinical study]. No To Shinkei 1988;40(4):373-82
   Google Scholar
• Gomis P, Graftieaux JP, Sercombe R, et al. Randomized, double-blind, placebo-controlled, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurosurg 2010;112(3):681-8
   Google Scholar
• Haley ECJr, Kassell NF, Torner JC. A randomized trial of nicardipine in subarachnoid hemorrhage: angiographic and transcranial Doppler ultrasound results. A report of the Cooperative Aneurysm Study. J Neurosurg 1993;78(4):548-53
   Google Scholar
• Barth M, Capelle HH, Munch E, et al. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series. Acta Neurochir (Wien) 2007;149(9):911-18; discussion 918
   Google Scholar
• Barth M, Pena P, Seiz M, et al. Feasibility of intraventricular nicardipine prolonged release implants in patients following aneurysmal subarachnoid haemorrhage. Br J Neurosurg 2011;25(6):677-83
   PubMed Web of Science ®Google Scholar
• Omeis I, Neil JA, Murali R, Abrahams JM. Treatment of cerebral vasospasm with biocompatible controlled-release systems for intracranial drug delivery. Neurosurgery 2008;63(6):1011-19; discussion 1019-1021
   Google Scholar
• Dalbasti T, Karabiyikoglu M, Ozdamar N, et al. Efficacy of controlled-release papaverine pellets in preventing symptomatic cerebral vasospasm. J Neurosurg 2001;95(1):44-50
   PubMed Web of Science ®Google Scholar
• Senbokuya N, Kinouchi H, Kanemaru K, et al. Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial. J Neurosurg 2013;118(1):121-30
   Google Scholar
• Wurm G, Tomancok B, Nussbaumer K, et al. Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo. Clin Neurol Neurosurg 2004;106(2):97-103
   PubMed Web of Science ®Google Scholar
• Hop JW, Rinkel GJE, Algra A, et al. Randomized pilot trial of postoperative aspirin in subarachnoid hemorrhage. Neurology 2000;54(4):872-8
   PubMed Web of Science ®Google Scholar
• van den Bergh WM, Algra A, Dorhout Mees SM, et al. Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid hemorrhage: the MASH Study. Stroke 2006;37(9):2326-30
   PubMed Web of Science ®Google Scholar
• Siironen J, Juvela S, Varis J, et al. No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial. J Neurosurg 2003;99(6):953-9
   PubMed Web of Science ®Google Scholar
• Shaw MD, Foy PM, Conway M, et al. Dipyridamole and postoperative ischemic deficits in aneurysmal subarachnoid hemorrhage. J Neurosurg 1985;63(5):699-703
   Google Scholar
• Suzuki S, Sano K, Handa H, et al. Clinical study of OKY-046, a thromboxane synthetase inhibitor, in prevention of cerebral vasospasms and delayed cerebral ischaemic symptoms after subarachnoid haemorrhage due to aneurysmal rupture: a randomized double-blind study. Neurol Res 1989;11(2):79-88
   Google Scholar
• Ono H, Mizukami M, Kitamura K, Kikuchi H. Ticlopidine: quo vadis? Subarachnoid hemorrhage. Agents Actions Suppl 1984;15:259-72
   Google Scholar
• Aoki C, Hattori Y, Tomizawa A, et al. Anti-inflammatory role of cilostazol in vascular smooth muscle cells in vitro and in vivo. J Atheroscler Thromb 2010;17(5):503-9
   PubMed Web of Science ®Google Scholar
• Niu PP, Yang G, Xing YQ, et al. Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Neurol Sci 2014;336(1-2):146-51
   Google Scholar
• Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJ. Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007(4):CD006184
   Google Scholar
• Simard JM, Aldrich EF, Schreibman D, et al. Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment. J Neurosurg 2013;119(6):1611-19
   PubMed Web of Science ®Google Scholar
• Buemi M, Cavallaro E, Floccari F, et al. The pleiotropic effects of erythropoietin in the central nervous system. J Neuropathol Exp Neurol 2003;62(3):228-36
   Google Scholar
• Helbok R, Ko SB, Schmidt JM, et al. Global cerebral edema and brain metabolism after subarachnoid hemorrhage. Stroke 2011;42(6):1534-9
   Google Scholar
• Guresir E, Vasiliadis N, Konczalla J, et al. Erythropoietin prevents delayed hemodynamic dysfunction after subarachnoid hemorrhage in a randomized controlled experimental setting. J Neurol Sci 2013;332(1-2):128-35
   Google Scholar
• Springborg JB, Moller C, Gideon P, et al. Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien) 2007;149(11):1089-101; discussion 1101
   Google Scholar
• Tseng MY, Hutchinson PJ, Richards HK, et al. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg 2009;111(1):171-80
   Google Scholar
• Rasmussen R, Juhler M, Wetterslev J. Effects of continuous prostacyclin infusion on regional blood flow and cerebral vasospasm following subarachnoid haemorrhage: statistical analysis plan for a randomized controlled trial. Trials 2014;15:228
   Google Scholar
• Oldfield EH, Loomba JJ, Monteith SJ, et al. Safety and pharmacokinetics of sodium nitrite in patients with subarachnoid hemorrhage: a phase IIa study. J Neurosurg 2013;119(3):634-41
   Google Scholar
• Sherman C. Intravenous nitrite infusion for reversal of cerebral vasospasm after subarachnoid hemorrhage. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT02176837 [Accessed 22 September 2014]
   Google Scholar
• Treggiari MM. Safety study of cervical sympathetic block for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT00930072 [Accessed 22 September 2014]
   Google Scholar
• Westermaier T. Hypercapnia to prevent secondary ischemia in SAH (SAHCO2). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01799525 [Accessed 22 September 2014]
   Google Scholar
• Mayor F, Bilgin-Freiert A, Connolly M, et al. Effects of remote ischemic preconditioning on the coagulation profile of patients with aneurysmal subarachnoid hemorrhage: a case-control study. Neurosurgery 2013;73(5):808-15; discussion 815
   Google Scholar
• Gonzalez N. Remote ischemic preconditioning in subarachnoid hemorrhage (RIPC-SAH). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000. Available from: https://clinicaltrials.gov/ct2/show/NCT01158508 [Accessed 22 September 2014]
   Google Scholar
• Cheng MF, Song JN, Li DD, et al. The role of rosiglitazone in the proliferation of vascular smooth muscle cells after experimental subarachnoid hemorrhage. Acta Neurochir (Wien) 2014;156(11):2103-9
   Google Scholar
• Zhang ZW, Yanamoto H, Nagata I, et al. Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries: proposed growth factor explanation of cerebral vasospasm. Neurosurgery 2010;66(4):728-35; discussion 735
   Google Scholar
• Shiba M, Suzuki H, Fujimoto M, et al. Role of platelet-derived growth factor in cerebral vasospasm after subarachnoid hemorrhage in rats. Acta Neurochir Suppl 2013;115:219-23
   Google Scholar
• Borel CO, McKee A, Parra A, et al. Possible role for vascular cell proliferation in cerebral vasospasm after subarachnoid hemorrhage. Stroke 2003;34(2):427-33
   PubMedGoogle Scholar
• Barth M, Capelle HH, Weidauer S, et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke 2007;38(2):330-6
   PubMed Web of Science ®Google Scholar
• Etminan N, Macdonald RL, Davis C, et al. Intrathecal application of the nimodipine slow-release microparticle system eg-1962 for prevention of delayed cerebral ischemia and improvement of outcome after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl 2015;120:281-6
   Google Scholar
• Shaw MD, Vermeulen M, Murray GD, et al. Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg 2000;93(6):992-7
   PubMedGoogle Scholar